United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Grows Stock Holdings in Gilead Sciences, Inc. $GILD

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,900 shares of the biopharmaceutical company’s stock after buying an additional 1,100 shares during the period. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s holdings in Gilead Sciences were worth $1,208,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. One Wealth Advisors LLC boosted its position in Gilead Sciences by 34.8% during the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after purchasing an additional 2,364 shares in the last quarter. Ariel Investments LLC raised its stake in shares of Gilead Sciences by 7.7% during the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock worth $48,229,000 after buying an additional 30,630 shares during the last quarter. Sivik Global Healthcare LLC boosted its position in shares of Gilead Sciences by 25.0% in the 2nd quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $5,544,000 after buying an additional 10,000 shares in the last quarter. Simplify Asset Management Inc. grew its stake in Gilead Sciences by 148.6% in the 2nd quarter. Simplify Asset Management Inc. now owns 52,890 shares of the biopharmaceutical company’s stock valued at $5,864,000 after acquiring an additional 31,618 shares during the last quarter. Finally, VeraBank N.A. acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $397,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Argus upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Wells Fargo & Company raised their price target on Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Finally, Truist Financial initiated coverage on Gilead Sciences in a research note on Monday. They set a “buy” rating and a $140.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $130.65.

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the transaction, the chief executive officer owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Deborah H. Telman sold 53,646 shares of Gilead Sciences stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the transaction, the executive vice president owned 43,676 shares in the company, valued at $5,365,596.60. The trade was a 55.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 115,146 shares of company stock worth $14,012,141. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Up 0.3%

NASDAQ GILD opened at $127.51 on Thursday. The company has a 50-day moving average of $119.36 and a 200-day moving average of $114.25. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a 12 month low of $88.57 and a 12 month high of $128.70. The company has a market cap of $158.20 billion, a P/E ratio of 25.40, a P/E/G ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is presently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.